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Thiazolyl cyclic peptide antibiotics are known for their poor aqueous solubility and unfavorable
pharmacokinetics (PK) and hence pose challenging tasks in developing these antibiotics as clinical
candidates. In the current paper, we report a possible way to address these challenges with
exempliﬁcation of our antibiotic PM181104. The approach was to prepare formulations with known
excipients, Polysorbate 80 (Tween 80, T-80) and PEG 400 through their varied stiochiometric combina-
tion in appropriate ratio to achieve acceptable osmolarity, pH and particle size of the formulation. Two
different sets of formulations were prepared with two distinct average particle diameters ranging from
32.8 to 465.4 nm. First, semi-transparent solutions with a particle size of 4100 nm were achieved by
keeping concentration of PEG 400 constant at 8% (w/v) and decreasing the amounts of T-80. Second, clear
colorless solutions with a particle size of o100 nm were achieved by keeping concentration of T-80
constant at 8% (w/v) and decreasing the amounts of PEG 400. In PK studies, intravenous administration of
formulation with particle size o100 nm to mice resulted in a two-fold increase in area under the plasma
concentration-time curve (AUClast) and concentration at time zero (C0), there by facilitating the selection
of suitable formulation for further efﬁcacy studies.
& 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The increasing number of infections caused by methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE) is a cause of great concern in antibiotic therapy
and predominantly, emerging mechanisms of new resistance,
making the next generation of antibiotics largely ineffective.
Hence, there exists a need for the development of novel class of
antibiotics with novel modes of action to overcome existing
resistance mechanisms and to effectively combat these serious
pathogens. Lately, thiazolyl cyclic-peptide antibiotics have been
emerging as an alternative class of antibiotics. They are known for
their potent in vitro antibacterial activity against a wide spectrum
of pathogens with their unique mode of action. However, in spite
of their potent in vitro antibacterial activity, till date these
compounds have not been developed for use in humans due to
low aqueous solubility and unfavorable pharmacokinetics [1–4].n open access article under the C
(V. Yemparala).We recently have reported a novel thiazolyl cyclic-peptide
antibiotic, PM181104 (Fig. 1) from marine microbial source [5,6].
The compound exhibits potent in vitro antibacterial activity against
a broad range of Gram-positive bacteria. The minimum inhibitory
concentration (MIC) values evaluated for the compound were in
nano-molar range. In in vivo studies of PM181104 in a BALB/c
murine septicemia model, the compound displayed 100% effective
dose (ED100) value of 2.5 mg kg1 of body weight against MRSA
and 10.0 mg kg1 against VRE, and in tissue or organ-speciﬁc
infection models showed reduction in bacterial titer comparable to
standard antibiotics [5,7]. In the current studies, suitable intrave-
nous (i.v) formulation development approaches have been ex-
plored. We consider that the i.v. route of administration facilitates
complete bioavailability and rapid action to treat the systemic
infections associated with the Gram-positive pathogens. True to
the behavior of naturally occurring thiazolyl peptide antibiotics,
PM181104 too exhibited poor aqueous solubility. To overcome
such difﬁculty, we made an effort to develop an i.v. formulation
using a non-ionic surfactant with co-solvent combination ap-
proach [8]. The advantage of this approach is that the combination
of surfactant and polymer may provide better protection against
solvent-mediated transformation than the surfactant or polymerC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Chemical structure of PM181104.
V. Yemparala et al. / Results in Pharma Sciences 4 (2014) 34–41 35alone [9]. However, in order to avoid the possible side effects such
as anaphylactic response and vascular irritability which may be
caused by surfactants, it is far safe to reduce the types and
stoichiometric concentration of the stabilizers used [10,11]. In-
deed, there is a set-in guideline by the FDA for choosing an
inactive ingredient [36]. Therefore, the major focus of our studies
was to formulate a dosage form that exhibits in vivo efﬁcacy with a
scope to minimize the excipient composition to an acceptable
extent. Initial attempts to achieve maximum drug exposure levels,
also inherently delivered a proportionately higher concentration of
excipients. Hence, there was a scope to bring down the excipient
levels in the deﬁned dosage delivery. Towards this effort, we
embarked upon studies involving the stoichiometric alteration of
two of the excipients namely, T-80 and PEG 400 which fall under
generally recognized as safe (GRAS) category, and comparing their
associated pharmacokinetics outcomes. We also evaluated the
effect of stiochiometric variations in these excipients on the
osmolarity, pH as well as particle size of the drug and its
implications on in vivo situation. These efforts resulted in the
identiﬁcation of an in vivo efﬁcacious formulation suitable for
parenteral administration.
The current paper describes the detailed studies of the devel-
opment of an in vivo efﬁcacious formulation using T-80 and PEG
400 and effect of stiochiometric variation of these excipients on
osmolarity, pH, particle size of the drug and the associated effect
on pharmacokinetics outcomes.2. Materials and methods
2.1. Materials
PM181104 was isolated and characterized in-house [5]. T-80
and PEG 400 were purchased from Croda Inc., USA. Sterile Water
for Injection was supplied by Nirma Ltd., India. Methanol and
acetonitrile solvents were of HPLC grade and were procured from
Merck.2.2. HPLC analysis
The reverse phase HPLC method was chosen for the quantita-
tive determination of the PM181104 in the formulations. Standard
and formulation samples were diluted with acetonitrile: methanol
(1:1; v/v) to obtain a ﬁnal concentration of 0.1 mg mL1 and then
injected a 10 mL injection volume directly to HPLC system. Agilent
1200 HPLC system (Agilent, USA) with a Kromasil 100 C18 analy-
tical column (1504.6 mm2, particle size 3.5 mm) was used for the
studies. The mobile phase was acetonitrile–water mixture (50:50,
v/v). The ﬂow rate was 1.0 mL min1 and the detection wave-
length was set to 309 nm. Percentage assay calculated with
respective to the chromatograms of standard and sample area.
2.3. Preparation of PM181104 formulation
PM181104 nanoparticles were prepared by anti-solvent pre-
cipitation technique, using water for injection (WFI) as the anti-
solvent [12]. By using this method nanoparticles can be manufac-
tured in the absence of mechanical forces which can have
inﬂuence on peptide stability [13]. For this, the speciﬁed amount
of T-80 was thoroughly mixed with the speciﬁed amount of PEG
400 under vortex followed by sonication, to form the excipient
mixture. The prepared excipient mixture was used to dissolve the
required amount of PM181104 using sonication carried out with
intermittent cooling (to maintain the temperature below 40 °C)
until a turbid free solution clear of any undissolved particulate
matter was obtained. The resultant clear, colorless and viscous
drug excipient mixture was then injected slowly and continuously
through drop wise addition using a buret to the anti-solvent under
rapid mixing (1000 rpm, magnetic stirrer). Precipitation of the
solid drug particles were occurred immediately upon contact with
the anti-solvent. The resulting formulation suspension was ster-
ilized by ﬁltering through 0.2 mm ﬁlter assembly connected to
vacuum. A total of eight formulations were made, and divided into
two sets based on their excipient composition. The ﬁrst set
consisted of formulations, made with a reduced concentration of
T-80. The second set consisted of reduced concentration of PEG
400. The optimization of the excipient composition in the ﬁrst set
of formulations (F1F5) was carried out using ternary composi-
tions containing water for injection (WFI), PEG 400 8% (w/v) and a
decreasing amounts of T-80 (8–0.05%) while maintaining the ﬁnal
concentration of PM181104 at 0.25 mg mL1. In the second set,
another three formulations (F6–F8) were prepared using ternary
compositions containing WFI, T-80 8% (w/v) and a decreasing
amounts of PEG 400 (6–0.5%) while retaining the ﬁnal concentra-
tion of the PM181104 at 0.5 mg mL1. The concentration of the
drug in the described formulation was reconﬁrmed using HPLC
analysis.
2.4. Determination of the particle size and polydispersity index
Particle size and polydispersity index (PDI) of the prepared
nanoparticles of PM181104 were measured immediately after
formulation ﬁltration process by dynamic laser light scattering
using particle size analyzer (Delsa Nano C, Nano-Zetasizer, Beck-
man Coulter, Miami, FL, USA) at back scattering measurement
angle of 165°. Samples were not diluted and measured at 25 °C.
The measurement was done in triplicate and size d90 was reported.
2.5. Osmolarity, zetapotential and pH measurements
The osmolarity, zetapotential and pH of the prepared formula-
tions of PM181104 were measured using an osmometer (Osmomat
030-3P, Gonotec, Germany), a Delsa Nano HC, Zeta Potential
Particle Analyzer (Beckman Coulter Inc., USA) and pH meter (pH
V. Yemparala et al. / Results in Pharma Sciences 4 (2014) 34–4136Tutor, Eutech Instruments Pte Ltd., Singapore), respectively. Each
measurement was performed in triplicate at 25 °C.
2.6. Morphology
The particle morphology of formulation F5 and F6 were
evaluated by transmission electron microscopy (TEM) (Model-
CM200, Make-PHILIPS). The formulation drops were added to a
300 mesh copper grid, then dried using IR light and then
examined by TEM.
2.7. Animals
Male Balb/c mice (18–25 g) bred in-house at Piramal Enter-
prises Limited, Goregaon, Mumbai, India were used. Mice were
maintained in a temperature of (2272 °C) and humidity (5575%)
controlled room with a 12 h light/dark cycle and free access to
standard diet and water. All mice used in this study were not
subjected to any form of treatment/medication. Guidelines of
Committee for the Purpose of Control and Supervision on Experts
on Animals (CPCSEA), Government of India, were followed and the
In-house Animal Ethics Committee approved all experimental
procedures. Animals were provided food and water ad libitum.
2.8. Pharmacokinetic studies
Mice were randomly and equally divided into eight groups
containing 24 mice each. Animals in Groups 1–5 were adminis-
tered with formulations F1–F5 intravenously at the dose of
2.5 mg kg1. Animals in Groups 6–8 were administered with
formulations F6–F8 intravenously at the dose of 5.0 mg kg1.
The administration was done via tail vein using a 1.0 mL tuberculin
syringe equipped with 27 G needle after dilation with ethanol
solution (70%). Blood samples (0.5 mL) were collected on ice from
three animals at each time point viz. 0.033, 0.083, 0.17, 0.25, 0.50,
0.75, 1 and 2 h post-dose using sodium citrate (10% v/v) as
anticoagulant. Plasma was separated by centrifugation of blood
samples at 10,000 rpm for 5 min at 4 °C and plasma samples were
stored at approximately 70 °C until bioanalysis by LC-MS/MS
method.
2.9. Plasma analysis
One hundred micro-liters of mouse plasma sample was ex-
tracted with 2.5 mL ethyl acetate on a vortex mixer for 5 min
followed by centrifugation for 5 min at 10,000 rpm at 20 °C. The
organic layer was transferred into another test tube and was
evaporated to dryness under a stream of nitrogen at 35 °C. The
samples were reconstituted in 200 mL solution of formic acid
(0.7%) in (acetonitrile: methanol: 1:1 v/v) and were vortexed, then
transferred into polypropylene vials. From this vial, 10 mL of the
sample was injected into the LC-MS/MS system for further
analysis.Table 1
Formulation characteristics and pharmacokinetic parameters obtained with formulatio
administration to mice at the dose of 2.5 mg kg1.
Formulation T-80 conc. % (w/v) Particle size D90 (nm)a Polydispersity index (
F1 8 37.9717.2 0.02870.166
F2 6 50.277.2 0.06670.100
F3 2 205.7774.1 0.18570.047
F4 1 291.3783.2 0.15670.055
F5 0.05 465.47117.7 0.21670.026
a Values are mean7S.D., n ¼ 3.
b Values are average, n ¼ 3.The samples were analyzed on Instrument Bruker Esquire 4000
LCMS/MS system. HPLC analysis system conditions were set as
follows: Kromasil 100 C18 analytical column (1504.6 mm2,
particle size 3.5 mm) mobile phase: acetonitrile:methanol:water:
acetic acid (60:30:10:1 v/v); ﬂow rate of the mobile phase: 0.4 mL
min1; measured wavelength: 309 nm.
2.10. Data analysis
Plasma concentrations were calculated using the Hystar soft-
ware, version 3.0, Build No. 129.0, Instrument Bruker Esquire 4000.
Pharmacokinetic parameters were determined by non-compart-
mental analysis using WinNonlin Professional version 6.1 (Phar-
sight Corporation, USA).3. Results and discussion
3.1. Optimizing the concentration of excipients using particle size
screening
In development of suitable formulations for hydrophobic drug
candidates, the type of excipients used and their stoichiometric
concentrations play a major role in deﬁning the delivery of that
drug candidate. The excipient composition inﬂuences the particle
size of the drug. Since particle size impacts in-vivo efﬁcacy, in our
studies we have focused on addressing the excipients used and
their stoichiometric optimization for delivery of our in-house
antibiotic candidate PM181104. The excipients used in prepared
formulations were as per regulatory limits. Yet, our objective was
to accomplish reduced concentrations of these excipients in
formulations to be at suitable level as excipients are known to
be proportionally related to their toxicity [14]. Prior to this,
PM181104 was formulated using Cremophor EL. But knowing the
toxicity associated with cremophor [15] and its subsequent repla-
cement, in our present work, we selected the two key excipients,
identiﬁed to be the best excipient combination among all of the hit
combinations and their excipient compositions were tested in
solubilizing the compound paclitaxel [16] i.e. non-ionic surfactant
T-80 along with the non-toxic solvent PEG 400 [17,18]. There were
reports, where Cremophor EL was not selected for the formulation
due to the adverse effects associated with its parenteral use.
Although, it exhibited highest potential to solubilize drug among
the non-ionic surfactants T-80 and Solutol HS 15 tested [19]. The
pharmacokinetics obtained with T-80 formulations was very
different than that with cremophor EL. In fact, due to much more
rapid breakdown by esterases, T-80 is a much more favorable
component for formulation/solubilization of poorly water soluble
agents than Cremophor EL [20]. In the current studies initially we
embarked on an effort to decrease T-80 concentration while
retaining the PEG 400 concentration at a constant level. In the
second effort, we ﬁxed the concentration of T-80 at 8% (w/v) and
tried to reduce PEG 400. With reference to former, to determinens F1–F5 having ﬁxed concentration of PEG 400 8% (w/v) following intravenous
PDI)a Zeta potential (mv)b AUClast (mg h mL1) C0 (μg mL1) t1/2 (min)
0.64 9.7034 106.1201 10.032
3.18 9.0627 81.2492 11.700
6.02 4.9812 13.7540 13.458
1.30 4.6235 41.0294 29.472
4.34 2.4780 66.5410 20.940
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tions containing ﬁxed 8% (w/v) PEG 400 and incrementally
decreased concentrations of T-80 viz., 8%, 6%, 2%, 1%, 0.05% (w/v)
were prepared and labeled as F1–F5. From the results of photon
correlation spectroscopic studies of these formulations, it was
observed that formulations F1 and F2 were exhibited signiﬁcant
smaller particle size (around 50 nm) and also reduced values of
polydispersity index (PDI) (Table 1). The two formulations F1 and
F2 with their respective PEG 400: T-80 ratios 8/8% and 8/6% (w/v),
respectively, had the proﬁciency of yielding smaller particle size or
nanoparticles of the drug. This may have occurred due to the
possible arrest of growth of nucleating crystals by the mentioned
surfactant T-80 or polymer PEG 400 through steric or electrostatic
mechanism [21]. On the other hand, formulations F3, F4 and F5
with respective PEG 400: T-80 ratios 8/2%, 8/1%, 8/0.05% (w/v)
showed signiﬁcantly higher particle size along with increased PDI
(Table 1). The transmission electron microscopic morphological
observation obtained for the formulation F5 revealed the higher
particle size of the drug in formulation (Fig. 3b). The aggregation
seen in formulations (F3 to F5) as a function of decreased
concentration of T-80 resulted in the increased particle size and
PDI which implies that maintenance of T-80 at 6% (w/v) is the
minimum necessary requirement [16], to maintain its steric
inhibitory effect on the formation of larger particles (Fig. 2). Other
possible mechanism that can be proposed in this context is the
existence of PM181104 as a non-ionized solute having better
solubility behavior in non-ionic surfactant. As per our observation
the effect of non-ionic surfactant concentration on the particle size
of the drug and subsequent solubility is in contrast with the
experimental observations made by [11].Fig. 2. The schematic representation demonstrates the steric hindrance of Tween-80 (T-
after i.v administration to mouse with varying number of proteins bound (shown as bluIn parallel studies, with reference to determining the effect of
reduced concentration of PEG 400, a set of three formulations F6,
F7 and F8 with their stiochiometric ratios of T-80: PEG 400 at 8/
6,8/1,8/0.5% (w/v) were prepared to check for particle size and
solubility of the drug. Surprisingly, the particle size and PDI for all
these formulations were signiﬁcantly small (around 50 nm) and
they were almost comparable to the values obtained for F1 and F2
(Table 2). The absence of any precipitation or aggregation even at
decreased concentration of PEG 400 indicates that the PEG 400
concentration has no effect what so ever on the particle size and
solubility of the drug. This implies that T-80 has an inﬂuencing
effect on nanoparticle generation due to its high molecular mass
(1310 g mol1), almost equivalent to that of PM181104
(1514 g mol1). Where as PEG 400 is a low molecular mass
(380–420 g mol1) molecule (Fig. 2). This difference in the mole-
cular mass appears to be having a steric effect on the nanoparticle
size and solubility as they have differential effect of adsorption
rate on the particle surface which may be a controlling factor in
the formulation of nanoparticles [22].
3.2. Size measurement and morphology
Physical appearances of the formulated solutions are shown in
Fig. 3a. The solutions in the ﬁrst two glass vials are clear and
colorless formulations followed by semi-transparent formulations
and then a set of clear and colorless stock of formulations. The
particle sizes of the formulations are tabulated in Tables 1 and 2.
As it can be seen from the data, clear solutions F1 and F2 show
particle size 50 or less than 50 nm.Whereas formulations F3, F4
and F5 with semi-transparent appearance show the particle size of
more than 200 nm. The TEM image taken for the formulations F580) and its inﬂuence on (a) particle size generation and (b) the fate of nanoparticles
e spheres on the nanoparticles).
Table 2
Formulation characteristics and pharmacokinetic parameters obtained with formulations F6–F8 having ﬁxed concentration of T-80 8% (w/v) following intravenous
administration to mice at the dose of 5.0 mg kg1.
Formulation PEG 400 conc. % (w/v) Particle size D90 (nm)a Polydispersity index (PDI)a Zeta potential (mv)b AUClast (mg h mL1) C0 (mg mL1) t1/2 (min)
F6 6 32.8721.7 0.02170.133 5.49 13.351 80.825 15.06
F7 1 49.4729.3 0.08570.028 6.18 15.369 104.919 24.168
F8 0.5 51.5715.8 0.06670.069 4.87 14.221 108.703 19.50
a Values are mean7S.D., n ¼ 3.
b Values are average, n ¼ 3.
1000 nm 100 nm
a
b c
Fig. 3. Characterizations of PM181104 formulations (a) the physical appearance of PM181104 in formulations F1–F8; (b) and (c) TEM morphology of formulation F5 (highest
particle size) and F6 (lowest particle size).
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from Fig. 3b, the size of the nanoparticles formed in F5 are larger
than 400 nm, where as for F6 the particle size observed was
around 50 nm or below (Fig. 3c). TEM scans for F5 and F6 are
shown in the ﬁgure as they represented higher and lower particle
size range morphology.
In Table 2, particle size of formulations F6, F7 and F8 (where
ﬁxed concentration of T-80 (8% w/v) is maintained with decreased
concentration of PEG 400), is approximately below 50 nm. These
observations suggest the required concentration of T-80 to get a
clear turbid free formulation. Any efforts to reduce its concentra-
tion below 6% w/v in the stoichiometry of T-80 and PEG 400 could
lead to a turbid formulation and subsequent higher nanoparticle
size.
3.3. Osmolarity, zetapotential and pH value
It is essential to maintain isotonicity for the intravenous
application of formulations. Non-ionic substances such as glycerol
or carbohydrate are recommended for use to maintain isotonicityin formulations. However, addition of salts such as sodium
chloride or potassium chloride would result in compression of
the diffused layer resulting in a reduction of the zeta potential and
consequently electrostatic destabilization [23]. In our experiments
we achieved this objective with non-ionic substances such as T-80
and PEG 400. Osmomat with freezing point depression technique
was used to measure the osmolarity of the formulations F1 to F8.
Formulations F1 and F2 showed higher osmolarity values 0.453
and 0.521 osmol kg1 respectively (Table 3). Where as F3 to F5
formulations were ranging from 0.325 to 0.412 osmol kg1
(Table 3). These formulations had osmolarity physiologically
similar to mouse blood and tissue ranging from 0.310–
0.340 osmol kg1[24] . No signiﬁcant change in the osmolarity
value was observed with decreasing concentrations of the T-80. On
the other hand, formulations F6 to F8 showed osmolarity ranging
from 0.270 to 0.107 osmol kg1 (Table 3). Among these, F6
formulation was closer to the osmolarity value of the mouse blood
and tissue, where as, other two formulations F7 and F8 were
very much below the required physiological isotonicity value.
This indicates that osmolarity increased proportionally with
Table 3
Osmolarity and pH values obtained with formulations F1–F8.
Formulation T-80 conc.%
(w/v)
PEG 400 conc.
% (w/v)
Osmolarity (Osmol/
kg)a
pH valuea
F1 8 8 0.52170.004 5.4970.29
F2 6 8 0.45370.005 5.0370.18
F3 2 8 0.33670.004 3.8870.08
F4 1 8 0.32570.002 3.7270.10
F5 0.05 8 0.41270.007 3.4570.06
F6 8 6 0.27070.003 5.4270.20
F7 8 1 0.15670.001 6.1670.07
F8 8 0.5 0.10770.002 6.4570.09
a Values are mean7S.D., n ¼ 3.
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constituent responsible for the osmolarity to the formulations.
The zeta potential is one of the important parameter that
underlines the aggregation behavior of the formulations. Accord-
ingly, formulations F1–F8 were subjected to zeta potential studies
to evaluate their aggregation behavior. The data obtained from the
studies are shown in Tables 1 and 2. The detailed analysis of the
zeta potential values indicates that the formulations F6–F8 carry a
reasonably good surface stability. And this observation is in good
agreement with other parameters measured for the same series.
The pH value of PM181104 formulations F1 to F8 was in the pH
range of 3.40–6.32 (Table 3). It was observed that the pH value was
decreased in proportion to the decreased concentrations of T-80.
However, these observations were in reverse with the decreasing
concentrations of PEG 400. Knowing that the extreme pH (both
alkaline and acidic) could be susceptible for peripheral vein
rupture, the pH of the infusion solution is generally expected to
be between 5 and 9 [25]. Interestingly, here in our studies, all the
efﬁcacious formulations fulﬁlled the pH criteria required for
intravenous administration.
3.4. Pharmacokinetic parameters
The plot of plasma concentration vs. time for PM181104 after
intravenous administration of formulations F1 to F8 in mice are
shown in Fig. 4. Formulations F1 and F2 showed higher plasma
exposure of the drug (AUClast averaged above 9.0 mg h mL1 and C0
averaged above 80 mg h mL1) are shown in Fig. 5a and b and the
corresponding pharmacokinetic parameter values in Table 1. An
important component of in vivo performance of nanoparticulate
systems is the opsonization and clearance of particles by the
mononuclear phagocytic system or the reticuloendothelial system
(RES). Opsonization is the process by which a particle becomes
covered with the so-called opsonin proteins [26]. The improved
behavior of these formulations (F1 and F2) could be due to the
stealth associated with smaller particle size of the drug (belowFig. 4. Plasma concentration-time proﬁle of PM181104 following intravenous
administration of formulations F1, F2, F3, F4 and F5 (2.5 mg kg1) and F6, F7 and
F8 (5.0 mg kg1) to BALB/c mice. Data are mean7S.D., n ¼ 3 mice.100 nm) that might help to escape the process of opsonization and
phagocytosis by reticuloendothelial system (RES) during blood
circulation, resulting in higher plasma concentration of the drug
(Fig. 2). Moreover, the size of the particle and its surface modiﬁca-
tion are able to strongly inﬂuence the proteins adsorbed on the
nanoparticle surface. Lower protein adsorption is seen with
smaller nanoparticles (70 nm) than with the larger nanoparticles
(Z200 nm) [27,28]. Studies have shown that smaller particle size
of the drug have an advantage as is evident from the fact that
colloidal drug delivery systems (CDDS) have a tendency to be
removed slowly from the blood circulation then the larger parti-
cles [10,29]. In vivo efﬁcacy of PM181104 with the formulation F1
in tissue or organ speciﬁc infection models (against MRSA and
VRE) showed a reduction in the bacterial titer when compared to
standard antibiotics (Linezolid and Vancomycin) [5].
However unlike the F1 and F2, the situation in case of
formulations F3–F5 was different. These formulations showed
lower plasma exposure compared to F1 and F2 (AUClast averaged
below 5.0 mg h mL1 and C0 averaged below 70 mg h mL1) are
shown in Fig. 5a and b and the corresponding pharmacokinetic
parameter values in Table 1. Knowing that these formulations are
semitransparent or relatively turbid and with bigger nanoparticle
size (above 200 nm), they might be quickly recognized and
phagocytosed by RES in blood circulation (Fig. 2). Pratten and
Llyod [30] have described that for a particle size of 30 nm, uptake
would occur through pinocytosis where as in case of drug particles
more than 100 nm, the process occurs through phagocytosis.
Moreover, particle size greater than 300 nm and beyond stealth
properties are minimal even in case of appropriate coating of drug
[31]. Accordingly, formulations F3–F5 failed to show good efﬁcacy
in the systemic infectious models (data not shown) even though,
these formulations exhibiting required feature like osmolarity,
which is more physiological to mouse blood and tissue. From
these observations without any ambiguity it is clear that T-80 has
a concentration dependent inﬂuence leading to changes in phar-
macokinetics of the drug candidate [32,33].
Formulations F6–F8 demonstrated higher plasma exposure
values (AUClast averaged above 13.0 mg h mL1 and C0 averaged
above 80 mg h mL1) are shown in Fig. 5a and b and the corre-
sponding pharmacokinetic parameter values in Table 2. They also
exhibited very effective in vivo efﬁcacy against MRSA and VRE. In
the BALB/c murine septicemia model one of these formulations
(F6) shown osmolarity value close to the mouse blood, displayed
an ED100 value of 2.5 mg kg1 against MRSA and 10.0 mg kg1
against VRE [5]. It was reported that, to avoid the rapid clearance
of nanoparticles from the blood, it is important to block the initial
process of opsonization. PEGylation is one of the widely used
strategies to prepare stealth particles that minimize or avoid
opsonization. PEGylation refers to adsorption, grafting, or covalent
attachment of hydrophilic PEG chains on the nanoparticle surface.
Covalent attachment or grafting is more effective than simple
adsorption of PEG to the particle surface for preventing opsoniza-
tion [26]. Generally, neutral and hydrophilic particles undergo
much lower opsonization than do charged and hydrophobic
particles [34]. While PEG is hydrophilic and has a neutral charge,
it prevents hydrophobic and electrostatic interactions with the
plasma proteins, thus avoiding opsonization. At the same time it
also indicates the minimal or negligible role of PEG 400 because of
its lack of capability to provide stealth to high molecular weight of
PM181104. For the effective stabilization of CDDS, most of the
studies showed that the protein adsorption decreased with an
increase of polymer molecular weight (MW). Usually, the PEG with
an MW of 2 kDa or higher provides better steric hindrance in
avoiding opsonization [26] and most of authors supported an
efﬁcient MW in the range of 1500–3500 Da [29]. The nanoparticles
formed in our studies could be due to simple adsorption of PEG
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Fig. 5. The inﬂuence of excipients of formulations F1–F8 (a) area under the plasma concentration-time curve (AUClast) (b) concentration at time zero (C0) (c) plasma half-lives
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V. Yemparala et al. / Results in Pharma Sciences 4 (2014) 34–4140400 rather than covalent attachment or grafting, unless PEGyla-
tion, PEG 400 acts here as a solubilizer rather than stabilizer and
have insigniﬁcant role in particle size, as well as in pharmacoki-
netic and dynamic studies. However, there is no or little scope of
minimizing the concentration of the PEG 400 due to its signiﬁcant
contribution to the osmolarity in the formulations.
The plasma half life values obtained for PM181104 after
intravenous injection of formulations of F1–F8 in mice are shown
in Fig. 5c and the corresponding values in Tables 1 and 2. As seen
from the data formulations F3 to F5 showed higher half life values.
This is in contrast to the observation made with respect to AUC
and Co, where these formulations shown lower values for these
parameters. Formulations F6–F8 showed proportionately higher
plasma half life values, comparable to formulations F1 and F2. On
the other hand, the observed higher half life values of F3–F5 could
possibly be explained as the nanoparticles taken up by RES might
dissolve slowly in the phagocytic cells followed by a slow release
of PM181104 into the blood circulation resulting in the higher half
life values [35]. However, this observed higher half life values did
not translate to higher AUC and Co in these semitransparent
formulations. AUC and Co are the important pharmacokinetic
parameters that are taken in to consideration for in vivo efﬁcacy
of antibiotics than the half life. In case of formulations F3–F5,
having seen higher half life one could expect better efﬁcacy, but
the observed poor efﬁcacy could be explained to the point that the
available PM181104 concentration could be at sub-therapeutic
level i.e. below minimum effective concentration (MEC) as much
of the drug is slowly released by the phagocytic cells. Although the
observed plasma concentrations were lower in case of formulation
F6 when compared to formulations F7 and F8, osmolarity is
equivalent to the physiological osmolarity of blood. Moreover the
pH of the formulation is in the required range for the intravenous
administration [25]. The observed transparency or clarity in the
formulation F6, and the smaller particle size were additional
features that were seen. Accordingly formulation F6 was consid-
ered as the best among the series and hence was selected for
further in vivo studies.
In summary, using excipients as a tool to modulate the
interaction of peptide molecules and physical appearance, photon
correlation spectroscopy and transmission electron microscope as
means to monitor the intensity of aggregation, we observed that
the rate of aggregation of peptides increases signiﬁcantly under
low concentrations of non-ionic surfactant (T-80). These results
are in coherence with observed pharmacokinetics, demonstrating
that the association of the peptide molecules is a critical event in
the plasma exposure levels.
4. Conclusion
Thiazolyl cyclic peptides have been receiving immense interest
in alternative antibiotic therapy. They display potent in vitroantibacterial activity against wide spectrum of Gram-positive
pathogens (MRSA, VRE etc.) and they are known for their unique
mode of action. Yet development of these antibiotics as clinical
candidates is limited due to their inherent drawbacks like poor
aqueous solubility and unfavorable pharmacokinetics. In the
current work, efforts have been put to address these issues
associated with one of our in-house thiazolyl peptide antibiotic
PM181104. The approach was to develop acceptable formulation
for complete efﬁcacy using known and appropriate excipients
classiﬁed under GRAS category. T-80 and PEG 400 were chosen
to develop suitable i.v. formulation with optimized excipient
concentrations. Through varying stiochiometric ratio of these
excipients, an acceptable i.v. formulation was achieved with
improved pharmacokinetics. In development of these acceptable
formulations for thiazolyl peptide antibiotic three important and
vital parameters are to be considered in to account
(i) transparency or clarity of the formulation; (ii) smaller particle
size of the formulation and (iii) minimum plasma concentration
levels of the formulated antibiotic. Accordingly, ﬁndings from the
current preclinical studies will play a signiﬁcant role in developing
effective formulation to achieve the desired therapeutic effects in
humans in future.Acknowledgments
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